Table 1. Clinicopathological characteristics of patients with glioma according to the expression of FZD7.
| Characteristics | FZD7 expression* | p value | |
|---|---|---|---|
| Low (n =38) | High (n = 38) | ||
| Age (years) | 0.64 | ||
| < 45 | 17 | 15 | |
| ≥ 45 | 21 | 23 | |
| Gender | 0.35 | ||
| Female | 18 | 14 | |
| Male | 20 | 24 | |
| Tumor size | 0.81 | ||
| < 5cm | 23 | 22 | |
| ≥ 5cm | 15 | 16 | |
| KPS | 0.11 | ||
| < 90 | 18 | 25 | |
| ≥ 90 | 20 | 13 | |
| Stage | < 0.01 | ||
| I & II | 25 | 11 | |
| III & IV | 13 | 27 | |
| Chemotherapy | 0.23 | ||
| Yes | 22 | 27 | |
| No | 16 | 11 | |
| Radiotherapy | 0.78 | ||
| Yes | 29 | 30 | |
| No | 9 | 8 | |
| Resection | 0.31 | ||
| Partial | 7 | 4 | |
| Subtotal | 11 | 17 | |
| Total | 20 | 17 | |
Abbreviation: KPS, Karnofsky performance status.
The median H-score of FZD7 was used as the cut-off to divide the study cohort into high expression and low expression groups.